- Home
- SIBN vs LYEL Comparison
SIBN vs LYEL Comparison
Compare SIBN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIBN | LYEL |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 886.9M | 504.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIBN | LYEL |
|---|---|---|
| Price | $15.58 | $22.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $25.00 | $25.00 |
| AVG Volume (30 Days) | ★ 554.4K | 90.4K |
| Earning Date | 02-23-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,578,000.00 | $41,000.00 |
| Revenue This Year | $21.66 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.27 | N/A |
| 52 Week Low | $12.50 | $7.65 |
| 52 Week High | $21.89 | $45.00 |
Technical Indicators
Market Signals| Indicator | SIBN | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 28.83 | 39.26 |
| Support Level | $15.64 | $22.00 |
| Resistance Level | $16.86 | $26.76 |
| Average True Range (ATR) | 0.47 | 1.76 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 9.77 | 11.04 |
Price Performance
Historical ComparisonAbout SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.